| id | Study | Lib. in paper | Exposition period | Study type |
Control type |
Tags | OR 95%CI | x1/n1 x0/n0 | no cases | no exposed | ROB | Ref. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| S15367 R63237 |
Bromley (Carbamazepine) (Epilepsy) (Controls exposed to LTG), 2023 | Neonatal special care admission | during pregnancy (anytime or not specified) | prospective cohort | exposed to other treatment, sick excluded | Adjustment: No |
0.54 [0.15;1.96] C excluded (control group) |
3/27 20/106 | 23 | 27 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S15368 R63250 |
Bromley (Carbamazepine) (Epilepsy) (Controls unexposed, sick), 2023 | Neonatal special care admission | during pregnancy (anytime or not specified) | prospective cohort | unexposed, sick | Adjustment: No | 1.54 [0.36;6.64] C | 3/27 6/80 | 9 | 27 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S9602 R34032 |
Aydin (Carbamazepine) (Controls exposed to Lamotrigine, sick), 2020 | Neonatal intensive care unit (NICU) | throughout pregnancy | retrospective cohort | exposed to other treatment, sick excluded | Adjustment: No |
0.38 [0.04;3.52] C excluded (control group) |
2/15 2/7 | 4 | 15 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S9603 R34042 |
Aydin (Carbamazepine) (Controls unexposed, sick), 2020 | Neonatal intensive care unit (NICU) | throughout pregnancy | retrospective cohort | unexposed, sick | Adjustment: No | 1.54 [0.19;12.32] C | 2/15 2/22 | 4 | 15 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S9760 R34846 |
Bank (Carbamazepine) (Mixed indications), 2017 | Admission to neonatal intensive care unit (NICU) or Special Care Nursery | during pregnancy (anytime or not specified) | prospective cohort | exposed to other treatment, sick | Adjustment: No | 1.67 [0.27;10.33] C | 2/8 6/36 | 8 | 8 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S9598 R33992 |
Artama (Carbamazepine) (Controls exposed to Lamotrigine, sick), 2013 | Admission to neonatal care unit | 3rd trimester | population based cohort retrospective | exposed to other treatment, sick excluded | Adjustment: No |
0.59 [0.36;0.96] C excluded (control group) |
89/904 24/154 | 113 | 904 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S9599 R34004 |
Artama (Carbamazepine) (Controls unexposed, disease free), 2013 | Admission to neonatal care unit | 3rd trimester | population based cohort retrospective | unexposed, disease free excluded | Adjustment: Yes |
1.44 [1.16;1.80] excluded (control group) |
89/904 49,612/689,482 | 49,701 | 904 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S9600 R34016 |
Artama (Carbamazepine) (Controls unexposed, sick), 2013 | Admission to neonatal care unit | 3rd trimester | population based cohort retrospective | unexposed, sick | Adjustment: Yes | 1.17 [0.88;1.55] | 89/904 152/1,708 | 241 | 904 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S9647 R34330 |
Viinikainen (Carbamazepine) (Controls unexposed, disease free) a, 2006 | Admission to a neonatal unit | throughout pregnancy | prospective cohort | unexposed, disease free | Adjustment: No | 1.15 [0.50;2.65] C | 6/72 1,822/24,778 | 1,828 | 72 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S9612 R34110 |
D'Souza (Carbamazepine) (Controls unexposed, disease free), 1991 | Idiopathic respiratory distress | throughout pregnancy | prospective cohort | unexposed, disease free excluded | Adjustment: No Matched |
24.60 [0.40;1512.72] C excluded (control group) |
0/3 0/62 | 0 | 3 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S9613 R34139 |
D'Souza (Carbamazepine) (Controls unexposed, sick), 1991 | Idiopathic respiratory distress | throughout pregnancy | prospective cohort | unexposed, sick | Adjustment: No | 3.00 [0.05;194.76] C | 0/3 0/8 | 0 | 3 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Total | 6 studies | 1.20 [0.92;1.55] | 2,090 | 1,029 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1: Carbamazepine) (Epilepsy) (Controls unexposed, sick; 2: Carbamazepine) (Controls unexposed, sick; 3: Carbamazepine) (Mixed indications; 4: Carbamazepine) (Controls unexposed, sick; 5: Carbamazepine) (Controls unexposed, disease free) ; 6: Carbamazepine) (Controls unexposed, sick;
Asymetry test p-value = 0.0165 (by Egger's regression)
slope=0.0942 (0.0301); intercept=0.3706 (0.0932); t=3.9757; p=0.0165
excluded 9612, 9598, 9599, 9602, 15367